logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical successfully concludes Sol-gel cannabinoid delivery program

PreveCeutical is developing lead cannabinoid formulations that could provide therapies to address central nervous system disorders using soluble gels

PreveCeutical Medical Inc. -
The firm is working on an extension of its cannabis sol-gel nasal program to address the coronavirus (COVID-19) pandemic

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) said it has successfully concluded its cannabinoid Sol-gel delivery program which looked at methods of delivering cannabinoid extracts to the central nervous system using soluble gels.

PreveCeutical’s chief science officer Dr Mak Jawadekar called the completion of the program a “very significant milestone” for the Vancouver-based company.

READ: PreveCeutical Medical turns to CBD sol-gel program to develop possible coronavirus treatment

“We are very excited about the therapeutic opportunities that will be derived from the program and look forward to progressing them through proof of concept studies,” Jawadekar said in a statement.

Soluble gels can be a safer, more reliable drug delivery agent for treatments like CBDs that are rapidly metabolized or would benefit from direct nose-to-brain delivery. Cannabinoids are generating interest in the medical community to treat a variety of central nervous system disorders such as neuropathic pain and multiple sclerosis.

PreveCeutical said it is planning to develop lead cannabinoid formulations that could provide therapies to address central nervous system disorders and has plans to commercialize the drugs following the conclusion of clinical trials.

The firm will provide more information when it receives the final Sol-gel program report from UniQuest Pty Limited, which will allow PreveCeutical to file patents related to the program.

PreveCeutical recently announced it is working on an extension of its cannabis sol-gel nasal program to address the coronavirus (COVID-19) pandemic, focusing on the expedited development of a CBD sol-gel to potentially reduce the possibility of coronavirus infections.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: PreveCeutical Medical Inc.

Price: 0.075 CAD

CSE:PREV
Market: CSE
Market Cap: $29.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 11/15/2019

2 min read